GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
https://www.zacks.com/stock/news/2324486/gsk-s-adc-drug-for-lung-cancer-gets-fda-s-breakthrough-tag?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2324486
Aug 20, 2024 - The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
0
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
https://www.zacks.com/stock/news/2323426/gilead-gild-obtains-fda-approval-for-pbc-drug-livdelzi?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323426
Aug 16, 2024 - Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
0
GSK trades in the green for seventh straight session
https://seekingalpha.com/news/4141217-gsk-trades-in-the-green-for-seventh-straight-session?source=feed_sector_healthcare
Aug 16, 2024 - GSK plc (GSK) stock up 0.65% at $41.28 on Friday, 17.8% rise in last 12 months. Analysts recommend Hold to Strong Buy.
0
GSK to seek dismissal of Zantac lawsuit after favorable court ruling in Florida
https://seekingalpha.com/news/4141043-gsk-seek-zantac-lawsuit-dismissal-florida?source=feed_sector_healthcare
Aug 16, 2024 - GSK (GSK) plans to seek dismissal of a Zantac lawsuit in Florida after a state court ruled that expert testimony was unreliable. Read more here.
0
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
https://www.zacks.com/stock/news/2321322/gsk-gsk-is-a-top-ranked-momentum-stock-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2321322
Aug 13, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
GSK wins FDA nod to expand Jemperli label in uterine cancer
https://seekingalpha.com/news/4132509-gsk-wins-fda-nod-expand-jemperli-label?source=feed_sector_healthcare
Aug 01, 2024 - GSK (GSK) stock gained as the company received the FDA nod to expand the label for its immunotherapy Jemperli targeted at endometrial cancer. Read more here.
0
Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market
https://www.cnbc.com/2024/08/01/moderna-mrna-earnings-q2-2024.html
Aug 01, 2024 - Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion.
0
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
https://www.zacks.com/stock/news/2314600/biotech-stock-roundup-bmy-gsk-biib-s-q2-results-vtvt-down-on-setback?cid=CS-ZC-FT-analyst_blog|stock_roundup-2314600
Aug 01, 2024 - Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
0
GSK shingles vaccine cuts dementia risk
https://seekingalpha.com/news/4130499-gsk-shingles-vaccine-cuts-dementia-risk?source=feed_sector_healthcare
Jul 30, 2024 - GSK's (GSK) shingles vaccine, Shingrix, shows significant reduction in dementia risk compared to Pfizer's (PFE) Pneumovax, according to new study data. Read more here.
0
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
https://www.zacks.com/stock/news/2312313/watch-these-5-biotech-stocks-for-q2-earnings-beat-or-miss?cid=CS-ZC-FT-analyst_blog|earnings_preview_esp-2312313
Jul 30, 2024 - Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
0